Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

235.79 +2.30 (+0.99%)
Streaming Delayed Price Updated: 11:58 AM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
News headline image
Beyond The Numbers: 17 Analysts Discuss Axsome Therapeutics Stock ↗
 
Via Benzinga
News headline image
Why Axsome Therapeutics Stock Is Skyrocketing Today ↗
Via The Motley Fool
News headline image
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' ↗
Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval. 
Via Benzinga
Topics Intellectual Property
News headline image
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Axsome Stock Rockets To Record High After Settling With Teva Over Depression Drug, Retail Optimism Swells ↗
Under the settlement terms, Teva will receive a license to sell a generic version of Auvelity starting March 31, 2039, if pediatric exclusivity is granted. 
Via Stocktwits
News headline image
12 Analysts Have This To Say About Axsome Therapeutics ↗
 
Via Benzinga
News headline image
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts ↗
 
Via Benzinga
News headline image
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
News headline image
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results ↗
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025. 
Via Benzinga
News headline image
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation ↗
Shares of dropped Monday on mixed test results for its Alzheimer's disease agitation treatment. 
Via Investor's Business Daily
News headline image
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says ↗
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile. 
Via Benzinga
News headline image
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript ↗
AXSM earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Bargain Stocks to Buy in a Market That's Priced for Perfection ↗
Yes, bargains can still be found in the stock market. 
Via The Motley Fool
News headline image
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
1 Under-the-Radar Biotech Stock to Buy and Hold ↗
It could be an industry giant in the making. 
Via The Motley Fool
News headline image
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.